...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Annual Financial Reporting
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Koo

Last years Zenith financials for 3rd Qtr ended 1/31/23 were released 4/6/23

Also should soon get news on RVX debenture which matures 5/13/24

2022 extension was reported 04/19/22

2023 extension was reported 03/20/23

What will this year bring? It's about time we received positive news

Chicagoest

5 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply